Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sagimet Biosciences, Inc. Class A (SGMT)
NASDAQ:SGMT
RESEARCH TOOLSreports
Sagimet Biosciences, Inc. Class A (SGMT) Stock Price & Analysis
294 Followers
SGMT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.13 - $20.71
Previous Close$3.33
Volume463.76K
Average Volume (3M)556.58K
Market Cap
$101.21M
Enterprise Value-$92.47M
Total Cash (Recent Filing)$193.71M
Total Debt (Recent Filing)$26.00K
Price to Earnings (P/E)―
Beta4.27
Next Earnings
Aug 19, 2024EPS Estimate
-$0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.20
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. Volume556,581
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-46.23
Enterprise Value/Gross Profit-46.23
Enterprise Value/Ebitda6.57
Forecast
1Y Price Target
$35.80Price Target Upside952.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Sagimet Biosciences, Inc. Class A News
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyDenifanstat has shown superior fibrotic effects in advanced F3 populations, which have a higher unmet medical need.
Clinical Trial DataNew data showed denifanstat is statistically significant in both NASH resolution and fibrosis improvement, reducing the risk for Phase 3 trials.
Market PositionSGMT is viewed as an attractive play on the broader NASH space, trading at a relative discount to competitors.
Bears Say
Competitive LandscapeThe recent approval of MDGL’s Rezdiffra and emerging data from the incretin class are quickly reshaping the competitive landscape.
Market UtilizationPotentially decreased utilization of later-to-market entrants such as denifanstat.
Stock PerformanceSince being added to the Americas Buy List, SGMT has decreased by 74% given the financing overhang despite positive data.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
SGMT FAQ
What was Sagimet Biosciences, Inc. Class A’s price range in the past 12 months?
Sagimet Biosciences, Inc. Class A lowest stock price was $2.13 and its highest was $20.71 in the past 12 months.
What is Sagimet Biosciences, Inc. Class A’s market cap?
Currently, no data Available
When is Sagimet Biosciences, Inc. Class A’s upcoming earnings report date?
Sagimet Biosciences, Inc. Class A’s upcoming earnings report date is Aug 19, 2024 which is in 29 days.
How were Sagimet Biosciences, Inc. Class A’s earnings last quarter?
Sagimet Biosciences, Inc. Class A released its earnings results on May 15, 2024. The company reported -$0.23 earnings per share for the quarter, beating the consensus estimate of -$0.387 by $0.157.
Is Sagimet Biosciences, Inc. Class A overvalued?
According to Wall Street analysts Sagimet Biosciences, Inc. Class A’s price is currently Undervalued.
Does Sagimet Biosciences, Inc. Class A pay dividends?
Sagimet Biosciences, Inc. Class A does not currently pay dividends.
What is Sagimet Biosciences, Inc. Class A’s EPS estimate?
Sagimet Biosciences, Inc. Class A’s EPS estimate is -$0.33.
How many shares outstanding does Sagimet Biosciences, Inc. Class A have?
Sagimet Biosciences, Inc. Class A has 30,393,396 shares outstanding.
What happened to Sagimet Biosciences, Inc. Class A’s price movement after its last earnings report?
Sagimet Biosciences, Inc. Class A reported an EPS of -$0.23 in its last earnings report, beating expectations of -$0.387. Following the earnings report the stock price went up 5.479%.
Which hedge fund is a major shareholder of Sagimet Biosciences, Inc. Class A?
Among the largest hedge funds holding Sagimet Biosciences, Inc. Class A’s share is Baker Bros Advisors LP. It holds Sagimet Biosciences, Inc. Class A’s shares valued at 7M.
---
Sagimet Biosciences, Inc. Class A Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$35.80 (952.94% Upside)
$35.80 (952.94% Upside)
Blogger Sentiment
Neutral
SGMT Sentiment 50%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 95.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.7%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
Fundamentals
Return on Equity
-26.35%
Trailing 12-Months
Asset Growth
613.79%
Trailing 12-Months
Company Description
Sagimet Biosciences, Inc. Class A
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
---
SGMT Stock 12 Month Forecast
Average Price Target
$35.80
▲(952.94% Upside)
Technical Analysis
Pieris Pharmaceuticals
―
Eton Pharmaceuticals
―
Ovid Therapeutics
―
Arrowhead Pharmaceuticals
―
Best Analysts Covering SGMT
1 Year
1 Year Success Rate
1/6 ratings generated profit
1 Year Average Return
-38.33%
reiterated a buy rating last month
Copying Ritu Baral's trades and holding each position for 1 Year would result in 16.67% of your transactions generating a profit, with an average return of -38.33% per trade.
---